These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 22921183)
1. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Van Cutsem E; Khayat D; Verslype C; Billemont B; Tejpar S; Meric JB; Soussan-Lazard K; Assadourian S; Cartot-Cotton S; Rixe O Eur J Cancer; 2013 Jan; 49(1):17-24. PubMed ID: 22921183 [TBL] [Abstract][Full Text] [Related]
2. Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study. Khayat D; Tejpar S; Spano JP; Verslype C; Bloch J; Vandecaveye V; Assadourian S; Soussan-Lazard K; Cartot-Coton S; Van Cutsem E Eur J Cancer; 2013 Mar; 49(4):790-7. PubMed ID: 23312881 [TBL] [Abstract][Full Text] [Related]
3. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335 [TBL] [Abstract][Full Text] [Related]
4. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA Oncology; 2016; 90(1):10-20. PubMed ID: 26492090 [TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. Xu J; Li Y; Sun X; Zhang D; Liu R; Ziti-Ljajic S; Shi D; Xue F; Le Bail N; Xu R Invest New Drugs; 2017 Aug; 35(4):463-470. PubMed ID: 28102464 [TBL] [Abstract][Full Text] [Related]
6. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439 [TBL] [Abstract][Full Text] [Related]
7. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804 [TBL] [Abstract][Full Text] [Related]
8. Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study. Ji D; Shen W; Li T; Wang H; Bai J; Cao J; Hu X Invest New Drugs; 2024 Aug; 42(4):462-470. PubMed ID: 39037543 [TBL] [Abstract][Full Text] [Related]
9. Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. Ghiringhelli F; Vincent J; Beltjens F; Bengrine L; Ladoire S Invest New Drugs; 2015 Dec; 33(6):1263-6. PubMed ID: 26490656 [TBL] [Abstract][Full Text] [Related]
10. Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. Salgado Fernández M; Pérez Hoyos MT; Díaz de Corcuera I; Vidal Arbués A; García de la Torre M Expert Opin Drug Saf; 2015 Aug; 14(8):1171-9. PubMed ID: 26076885 [TBL] [Abstract][Full Text] [Related]
11. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. Falcone A; Masi G; Allegrini G; Danesi R; Pfanner E; Brunetti IM; Di Paolo A; Cupini S; Del Tacca M; Conte P J Clin Oncol; 2002 Oct; 20(19):4006-14. PubMed ID: 12351598 [TBL] [Abstract][Full Text] [Related]
12. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Tabernero J; Van Cutsem E; Lakomý R; Prausová J; Ruff P; van Hazel GA; Moiseyenko VM; Ferry DR; McKendrick JJ; Soussan-Lazard K; Chevalier S; Allegra CJ Eur J Cancer; 2014 Jan; 50(2):320-31. PubMed ID: 24140268 [TBL] [Abstract][Full Text] [Related]
13. A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. Berlin J; Ramanathan RK; Strickler JH; Subramaniam DS; Marshall J; Kang YK; Hetman R; Dudley MW; Zeng J; Nickner C; Xiong H; Komarnitsky P; Shepherd SP; Hurwitz H; Lenz HJ Br J Cancer; 2018 Apr; 118(7):938-946. PubMed ID: 29527010 [TBL] [Abstract][Full Text] [Related]
14. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138 [TBL] [Abstract][Full Text] [Related]
15. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086 [TBL] [Abstract][Full Text] [Related]
16. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. Chiang NJ; Chao TY; Hsieh RK; Wang CH; Wang YW; Yeh CG; Chen LT BMC Cancer; 2016 Nov; 16(1):907. PubMed ID: 27871319 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. Van Cutsem E; Labianca R; Bodoky G; Barone C; Aranda E; Nordlinger B; Topham C; Tabernero J; André T; Sobrero AF; Mini E; Greil R; Di Costanzo F; Collette L; Cisar L; Zhang X; Khayat D; Bokemeyer C; Roth AD; Cunningham D J Clin Oncol; 2009 Jul; 27(19):3117-25. PubMed ID: 19451425 [TBL] [Abstract][Full Text] [Related]
18. Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer. Yusof MM; Abdullah NM; Sharial MM; Zaatar A Asian Pac J Cancer Prev; 2016; 17(3):973-8. PubMed ID: 27039822 [TBL] [Abstract][Full Text] [Related]
19. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]